Geron Corporation
General ticker "GERN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $936.8M (TTM average)
Geron Corporation follows the US Stock Market performance with the rate: 14.9%.
Estimated limits based on current volatility of 3.2%: low 1.39$, high 1.48$
Factors to consider:
- Total employees count: 229 (+62.4%) as of 2024
- Top business risk factors: Regulatory and compliance, Supply shortage, Manufacturing risks, Economic downturns and volatility, Liquidity and credit risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.07$, 2.74$]
- 2026-12-31 to 2027-12-31 estimated range: [1.31$, 3.14$]
Financial Metrics affecting the GERN estimates:
- Positive: with PPE of -12.3 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: 19.19 < Shareholder equity ratio, % of 39.59 <= 42.57
- Positive: Investing cash flow per share per price, % of 11.87 > -0.60
- Positive: Inventory ratio change, % of -33.46 <= -0.75
Short-term GERN quotes
Long-term GERN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.24MM | $76.99MM | $183.88MM |
| Operating Expenses | $194.18MM | $250.73MM | $252.47MM |
| Operating Income | $-193.94MM | $-173.73MM | $-68.58MM |
| Non-Operating Income | $9.82MM | $-0.84MM | $-14.91MM |
| Interest Expense | $8.31MM | $18.50MM | $32.66MM |
| R&D Expense | $125.05MM | $103.74MM | $71.43MM |
| Income(Loss) | $-184.13MM | $-174.57MM | $-83.50MM |
| Net Income(Loss)* | $-184.13MM | $-174.57MM | $-83.50MM |
| Stockholders Equity | $247.95MM | $280.32MM | $225.87MM |
| Inventory | $0.00MM | $38.71MM | $0.00MM |
| Assets | $394.08MM | $593.78MM | $570.54MM |
| Operating Cash Flow | $-167.74MM | $-218.62MM | $-111.04MM |
| Capital expenditure | $0.83MM | $0.68MM | $0.05MM |
| Investing Cash Flow | $-180.32MM | $-106.00MM | $107.25MM |
| Financing Cash Flow | $362.02MM | $334.37MM | $2.27MM |
| Earnings Per Share** | $-0.32 | $-0.27 | $-0.13 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.